Publication Name	World Journal of Pharmacology
Manuscript ID	22731
Country	Australia

Received	2015-09-20 15:30
Peer-Review Started	2015-09-22 18:50
To Make the First Decision	2015-10-27 11:16
Return for Revision	2015-10-30 16:33
Revised	2015-11-26 15:41
Second Decision	2015-12-18 11:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-01-04 16:40
Articles in Press	2016-01-04 16:40
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-02-23 13:37
Publish the Manuscript Online	2016-03-04 15:35

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Review
Article Title	Allosteric modulation of cholinergic system: Potential approach to treating cognitive deficits of schizophrenia
Manuscript Source	Invited Manuscript
All Author List	Shaun Hopper, Madhara Udawela, Elizabeth Scarr and Brian Dean
Funding Agency and Grant Number
Corresponding Author	Shaun Hopper, MSc, the Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Gate 11 Royal Parade, Melbourne, Victoria 3052, Australia. shaun.hopper@florey.edu.au
Key Words	Central nervous system; Antipsychotic; Allosteric; Cholinergic; Schizophrenia; Mutagenesis; Cognition; Muscarinic
Core Tip	Schizophrenia is a psychiatric disorder affecting approximately 1% of the world population. Current treatments inadequately redress the cognitive impairments associated with the disease. In light of that we discuss the role of the cholinergic system, in particular the muscarinic M1 receptor, in schizophrenia and cognition and how allosteric compounds are being developed to address this undertreated aspect of the disease. We also discuss and compile mutagenesis studies of the muscarinic M1 receptor and how they relate to allosteric binding and function.
Publish Date	2016-03-04 15:35
Citation	Hopper S, Udawela M, Scarr E, Dean B. Allosteric modulation of cholinergic system: Potential approach to treating cognitive deficits of schizophrenia. World J Pharmacol 2016; 5(1): 32-43
URL	http://www.wjgnet.com/2220-3192/full/v5/i1/32.htm
DOI	http://dx.doi.org/10.5497/wjp.v5.i1.32

Full Article (PDF)	WJP-5-32.pdf
Full Article (Word)	WJP-5-32.doc
Manuscript File	22731-Review.docx
Answering Reviewers	22731-Answering reviewers.pdf
Audio Core Tip	22731-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	22731-Conflict-of-interest statement.pdf
Copyright License Agreement	22731-Copyright assignment.pdf
Supplementary Material	Supplementary_Material_20150919161435.docx
Peer-review Report	22731-Peer-review(s).pdf
Scientific Misconduct Check	22731-Scientific misconduct check.pdf
Scientific Editor Work List	22731-Scientific editor work list.pdf